Sulindac
- 3 December 1982
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 248 (21) , 2864-2867
- https://doi.org/10.1001/jama.1982.03330210046033
Abstract
Three patients experienced rapidly reversible azotemia related to the use of naproxen or ibuprofen but tolerated full-dose sulindac. This article discusses renal toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs), with emphasis on the role of inhibition of prostaglandin synthesis, and reviews evidence supporting a renal-sparing property of sulindac. The current literature assumes that all NSAIDs possess a similar potential for renal toxicity. The data presented suggest that sulindac has less potential for renal toxicity and may be the preferred NSAID for use in patients with impaired renal function. (JAMA1982;248:2864-2867)Keywords
This publication has 7 references indexed in Scilit:
- Reversible Acute Renal Failure from Combined Triamterene and IndomethacinAnnals of Internal Medicine, 1982
- Arachidonic acid metabolism, prostaglandins and the kidneyThe American Journal of Medicine, 1982
- Renal effects of drugs that inhibit prostaglandin synthesisKidney International, 1980
- Review of the Pharmacokinetics and Metabolism of Zomepirac in Man and AnimalsThe Journal of Clinical Pharmacology, 1980
- Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandinBiochemical and Biophysical Research Communications, 1977
- Aspirin-Induced Depression of Renal FunctionNew England Journal of Medicine, 1977
- Naproxen Metabolism in ManThe Journal of Clinical Pharmacology, 1975